Vita 34 AG, DE000A0BL849

Vita 34 AG, DE000A0BL849

08.09.2017 - 13:19:39

Vita 34 completes Management Board with the return of Falk Neukirch

Vita 34 completes Management Board with the return of Falk Neukirch

- Falk Neukirch CFO of Vita 34 AG again from 11 September

- Personnel changes in Management and Supervisory Board completed

Leipzig, September 08, 2017 - Vita 34 AG (WKN A0BL84) has agreed with Mr. Falk Neukirch about a return to the company's Management Board. On 11 September, he will take over the position of Chief Financial Officer in the company, which he previously held from October 2015 until the end of April 2017.

"Just a few weeks after the change in the Management Board in June we contacted Falk Neukirch again and discussed whether he could imagine a return to the company," explains Dr. Wolfgang Knirsch, CEO of Vita 34 since June. "I am very pleased that he is back on board. We are a well-established team and over the past few years he has demonstrated that he has a firm grip on all areas of our financial department. "

With the changes announced today, the company sees the personnel conversion of the Executive Board and the Supervisory Board as completed and Vita 34 optimally positioned for the further growth course. "After the numerous personnel issues of the past months, our structures are now clearly consolidated," Knirsch concludes. "We are now fully focused on the business and our medium-term growth strategy."

Contact: Ingo Middelmenne Investor Relations Vita 34 AG Deutscher Platz 5a 04103 Leipzig Phone: +49 (0341) 48792 - 0 Email: ingo.middelmenne@vita34.de

Company Profile

Vita 34 was founded in 1997 as the first private umbilical cord blood bank in Europe and, as a complete provider, offers collection logistics, preparation and storage of umbilical cord blood and cord tissue. The basis for its successful work is an outstanding position in the technological segment of cryo-preservation. Here, cells and tissue are preserved alive at some -190ºC for long periods of time, and can be used if needed in the context of medical treatment. More than 200,000 customers are already taking advantage of this offering and have provided for their children with a stem cell deposit at Vita 34.

08.09.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English

Company: Vita 34 AG Deutscher Platz 5a 04103 Leipzig

Germany Phone: +49(0341)48792-40 Fax: +49(0341)48792-39 E-mail: ir@vita34.de Internet: www.vita34.de ISIN: DE000A0BL849 WKN: A0BL84 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange   End of News DGAP News Service

607993  08.09.2017 

@ dgap.de